Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

March 26, 2021 1:00 pm

Ixabepilone plus bevacizumab yielded responses in a third of patients.

By Ian Ingram

Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.

Median progression-free … Read more

Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

March 21, 2021 5:00 pm

Responses in 37% of patients with AVB-500, higher without prior bevacizumab.

By Charles Bankhead

More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24, 2021 6:00 pm

An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

By Courtney Marabella… Read more

Wee1 Inhibitor Gets Win in Tough-to-Treat Ovarian Cancer

January 25, 2021 5:00 pm

By Ian Ingram

Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.

For the primary endpoint of progression-free survival … Read more

Phase I Data of XMT-1536 Supports Continued Development in Ovarian Cancer

September 17, 2020 1:00 pm

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more

Survival and Clinical Outcomes of Patients with Ovarian Cancer Who Were Treated on Phase 1 Clinical Trials

July 24, 2020 3:00 pm

Corr BR, Moroney M, Sheeder J, et al

Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single-institution series with 132 patients to … Read more

Navicixizumab Combo Shows Benefit in Heavily Pretreated Ovarian Cancer

April 2, 2020 10:45 am

By Jason M. Broderick

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study.

The data build on positive … Read more

Siravatinib/Tislelizumab Signals Efficacy in Patients With Platinum-Resistant Ovarian Cancer

December 19, 2019 6:00 pm

By Nichole Tucker

Preliminary data showed that the combination of sitravatinib (MGCD516) and tislelizumab (BGB-A317) is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18, 2019 3:30 pm

By Kristie L. Kahl

Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more

ImmunoGen’s Ovarian Cancer Drug Misses Phase III Primary Endpoint

March 4, 2019 5:00 pm

US-based biotechnology company ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.

The study failed to meet its primary endpoint of progression-free survival (PFS). Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more